All In Biotech

Drug Trial Radar · NCT01802333

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 754 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

754

Actual

Start

Feb 12, 2013

Primary completion

Jun 15, 2017

Study completion Jun 15, 2017

Sponsor

Sponsor type
NIH
First posted
Mar 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.

Conditions

  • Acute Myeloid Leukemia
  • Untreated Adult Acute Myeloid Leukemia

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Undergo allogeneic transplant

  • CytarabineDrug

    Given IV

  • Daunorubicin HydrochlorideDrug

    Given IV

  • IdarubicinDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • VorinostatDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS)Time frame: EFS assessed for up to 5 years, 2 year EFS reported
  2. Rate of Allogeneic HCTTime frame: Up to 5 years

Locations

447 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Medical Center-University Campus

    Tucson, Arizona

  • Yuma Cancer Center

    Yuma, Arizona

  • Mercy Cancer Center-Hot Springs

    Hot Springs, Arkansas

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Northside Hospital-Forsyth

    Cumming, Georgia

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho

  • Saint Luke's Mountain States Tumor Institute

    Boise, Idaho

  • Kootenai Medical Center

    Coeur d'Alene, Idaho

  • Saint Luke's Mountain States Tumor Institute - Fruitland

    Fruitland, Idaho

  • Saint Luke's Mountain States Tumor Institute - Meridian

    Meridian, Idaho

  • Saint Luke's Mountain States Tumor Institute - Nampa

    Nampa, Idaho

  • Kootenai Cancer Center

    Post Falls, Idaho

  • Kootenai Cancer Clinic

    Sandpoint, Idaho

  • Saint Luke's Mountain States Tumor Institute-Twin Falls

    Twin Falls, Idaho

  • Saint Joseph Medical Center

    Bloomington, Illinois

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois

Showing 40 of 447 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.